Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 1 study evaluating the safety and...
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant – an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine.
Allergan plc , a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical...
Guidelines extended to improve the use of feedback from patients in clinical trials.
Researchers recommend changes to international guidelines used in the development of clinical trials in an effort to obtain useful information about the impact of...
Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium
MacroGenics, Inc. a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced presentation of data...
Medivir completes pre-clinical safety studies with MIV-818 to treat hepatocellular carcinoma
Medivir AB, a research-based pharmaceutical company, announced the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I...
Akcea begins phase 2b study of AKCEA-APOCIII-LRx in patients with hypertriglyceridemia & established CVD
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by...
Avelas completes patient enrollment in phase 2 study of AVB-620 in women with primary, nonrecurrent breast cancer undergoing surgery
Avelas Biosciences, a clinical stage oncology-focused company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, announced the...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...
